PICCOLO, RAFFAELE
 Distribuzione geografica
Continente #
NA - Nord America 1.514
EU - Europa 805
AS - Asia 610
AF - Africa 44
SA - Sud America 3
OC - Oceania 1
Totale 2.977
Nazione #
US - Stati Uniti d'America 1.459
SG - Singapore 340
IT - Italia 299
CN - Cina 260
NL - Olanda 248
IE - Irlanda 61
FI - Finlandia 56
CA - Canada 54
CI - Costa d'Avorio 44
DE - Germania 38
BE - Belgio 31
SE - Svezia 26
GB - Regno Unito 19
FR - Francia 7
IN - India 5
VN - Vietnam 4
CZ - Repubblica Ceca 3
PE - Perù 3
RU - Federazione Russa 3
AT - Austria 2
CH - Svizzera 2
HU - Ungheria 2
RO - Romania 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
DK - Danimarca 1
GR - Grecia 1
MX - Messico 1
NO - Norvegia 1
PL - Polonia 1
TR - Turchia 1
Totale 2.977
Città #
Chandler 283
Singapore 269
Amsterdam 246
Naples 116
Millbury 115
Nanjing 102
Ashburn 71
Des Moines 70
Boston 64
Princeton 64
Santa Clara 56
Lawrence 51
Ottawa 50
Beijing 49
Wilmington 31
Courcelles 28
Napoli 24
Hebei 21
Milan 18
Shenyang 17
Jiaxing 15
Tianjin 15
Nanchang 14
Kronberg 12
Lappeenranta 12
Changsha 10
London 10
Jacksonville 9
Norwalk 8
Kunming 7
San Giuseppe Vesuviano 7
Seattle 7
Torre del Greco 7
Boardman 6
Council Bluffs 5
Frankfurt am Main 5
Sant'anastasia 5
Woodbridge 5
Caivano 4
Houston 4
Rome 4
Washington 4
Brussels 3
Chicago 3
Dallas 3
Dublin 3
Falls Church 3
Helsinki 3
Lima 3
Palermo 3
Pune 3
Redmond 3
Toronto 3
Trecase 3
Assago 2
Atlanta 2
Bologna 2
Brno 2
Budapest 2
Casavatore 2
Catania 2
Dong Ket 2
Eboli 2
Edinburgh 2
Eindhoven 2
Fairfield 2
Giugliano in Campania 2
Guangzhou 2
Ho Chi Minh City 2
Leipzig 2
Mugnano di Napoli 2
Paris 2
Prineville 2
Reggio Emilia 2
Simi Valley 2
Stockholm 2
Sunnyvale 2
Turin 2
Vienna 2
Villaricca 2
West Jordan 2
Ankara 1
Ann Arbor 1
Arezzo 1
Aurisina Cave 1
Avellino 1
Aversa 1
Bengaluru 1
Bern 1
Buffalo 1
Cantù 1
Cerreto Guidi 1
Changchun 1
Copenhagen 1
Crispano 1
Delhi 1
Fort Worth 1
Fremont 1
Ghedi 1
Glasgow 1
Totale 2.029
Nome #
1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention 84
A cross-sectional study evaluating hospitalization rates for chronic limb-threatening ischemia during the COVID-19 outbreak in Campania, Italy 48
A New Approach to Percutaneous Coronary Revascularization in Patients Requiring Undeferrable Non Cardiac Surgery. 45
Coronary stenting early before non-cardiac surgery: is the endothelial progenitor cell capturing coronary stent a solution? 45
ADDED Index or percentage diameter of residual coronary stenosis to risk-stratify patients presenting with STEMI 45
Bleeding risk in patients undergoing percutaneous coronary intervention: how to define, identify and treat high-risk patients 42
A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery 40
Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis. 40
Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry 38
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial 37
Extent of cardiac damage and mortality in patients undergoing transcatheter aortic valve implantation 37
Antiplatelet theRapy after Genous EPC-capturing coroNary stenT implantatiOn: The ARGENTO Study: a prospective, multicenter registry. 36
Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease. 35
Coronary stenting early before non-cardiac surgery: is the endothelial progenitor cell capturing coronary stent a solution? 35
Title The GPIIIA PIA2 Polymorphism is Associated with an Increased Risk of Cardiovascular Adverse Event 35
Unrestricted use of endeavour resolute stent in daily clinical practice: a single-centre prospective registry. 35
Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients with Acute ST-Segment Elevation Myocardial Infarction: Insights from the 2-Year Follow-Up of the BIOSCIENCE Trial 35
Angiographic improvement in STEMI reperfusion: a single centre experience 34
Predicting Recurrent Restenosis After Drug-eluting Balloon: A First Step Toward Personalized Treatment 34
Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 34
Coronary angioplasty with stenting for acute coronary syndrome in patients with isolated single coronary artery: a report of two cases 33
Angiographic complexity of coronary artery disease according to syntax score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: A substudy of the bioscience trial 33
Coronary artery disease and myocardial revascularization in patients undergoing transcatheter aortic valve replacement 33
Preprocedural high-sensitivity cardiac Troponin T and clinical outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention 33
Predictors of adherence to composite therapy after acute coronary syndromes 33
Antithrombotic therapy and vascular access site: A choice not mutually exclusive 32
Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with st-segment-elevation myocardial infarction: Primary results of the FABOLUS-FASTER trial 32
A new approach to percutaneous coronary revascoularization in patient requiring undeferrable non-cardiac surgery. 31
Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials 31
Effect of an invasive strategy on outcome in patients ≥75 years of age with non-St-elevation acute coronary syndrome 31
Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials. 30
Adenosine-induced torsade de pointes complicating a fractional flow reserve measurement in a right coronary artery intermediate stenosis. 30
CardioPulse: Different bleeding scores and which one should we use? 30
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction 30
Effect of drug-eluting stents in patients with acute ST-segmentelevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. 29
Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates 29
Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation 29
What About Pharmacologic Therapy? 29
Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention. A meta-analysis of randomised clinical trials 28
Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis 28
Myocardial expression of FOXO3a-Atrogin-1 pathway in human heart failure. 27
Everolimus- versus first generation drug-eluting stents: the never-ending story of searching for a winner in the "limus family". 27
Pharmacotherapeutic Considerations for the Use of Prasugrel and Ticagrelor to Reduce Stent Thrombosis in Patients With Acute Coronary Syndrome. 27
β2-Adrenergic receptor stimulation improves endothelial progenitor cell-mediated ischemic neoangiogenesis. 27
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial 27
Bioresorbable scaffolds: in search of event-free dissolution 27
From biodegradable polymers to bioresorbable vascular scaffolds: available evidence in the current era of new-generation DES 26
Long-Term Assessment of Bioresorbable Coronary Scaffolds: Disappearing Stents, Reappearing Atherosclerosis ∗ 26
Dual antiplatelet therapy in percutaneous coronary intervention: A tale of 2 decades with new perspectives in the era of new-generation drug-eluting stents 26
The ultimaster biodegradable-polymer sirolimus-eluting stent: An updated review of clinical evidence 26
Sirolimus- versus paclitaxel-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. 25
Melatonin is associated with reverse remodeling after cardiac resynchronization therapy in patients with heart failure and ventricular dyssynchrony 25
Effects on short and long term outcome of the genous bio-engineered stent in patients undergoing major non cardiac surgery: results of a pilot study 24
No-Reflow Phenomenon: Pathophysiology, Diagnosis, Prevention, and Treatment. A Review of the Current Literature and Future Perspectives. 24
Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention 24
Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial 23
One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients 22
Is direct stenting superior to stenting with predilation inpatients treated with percutaneous coronary intervention? Results from a meta-analysis of 24 randomised controlled trials. 22
Low-dose aspirin to reduce the risk for myocardial infarction among patients with coronary stents undergoing noncardiac surgery 22
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: The GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) 22
Myocardial mass affects diagnostic performance of non-hyperemic pressure-derived indexes in the assessment of coronary stenosis 21
Long-term clinical outcomes following sirolimus-eluting stent implantation in patients with acute myocardial infarction. A meta-analysis of randomized trials. 21
Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized trials. 21
Mortality reduction with transradial approach in patients with ST-segment elevation myocardial infarction: is the randomized evidence conclusive? 21
Effects of baseline coronary occlusion and diabetes mellitus in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 21
Comparative effectiveness and safety of new-generation versus early-generation drug-eluting stents according to complexity of coronary artery disease: A patient-level pooled analysis of 6,081 patients 21
Evaluation and percutaneous treatment of severely calcified coronary lesions 21
Stable coronary artery disease: Revascularisation and invasive strategies 20
The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events 19
Transradial versus Transfemoral Approach in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials 19
Reperfusion Correlates and Clinical Outcomes of Right Ventricular Dysfunction in Patients With Inferior ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention 19
Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis 19
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: A meta-analysis of randomized trials 19
Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection 19
Percutaneous coronary intervention in patients with COVID-19 and acute coronary syndrome: What if the old normal became the new normal? 19
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial 18
Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial 18
Patent foramen ovale closure vs. medical therapy for recurrent stroke prevention: Evolution of treatment effect during follow-up 18
Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction 18
Mortality after Bleeding versus Myocardial Infarction in Coronary Artery Disease: A Systematic Review and Meta-Analysis 18
Impact of COVID-19 pandemic on timing and early clinical outcomes of transcatheter aortic valve implantation 17
Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions 17
New perspectives for transcatheter aortic valve implantation: more than a "simple" alternative to surgery. 17
Relationship between changes in platelet reactivity and ischemic?events following percutaneous coronary intervention: A?meta-regression analysis of 30 randomized trials 17
Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation 17
A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study 17
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent for percutaneous coronary revascularization: 2-year results of the BIOSCIENCE trial 17
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting 17
Periprocedural myocardial infarction in patients undergoing complex versus noncomplex percutaneous coronary intervention 16
From bare metal to barely anything: An update on coronary stenting 16
Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: A subgroup analysis of the PRODIGY randomized clinical trial 16
Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement 16
The Debut of Sirolimus-Eluting Balloons: The Final Nail in the Coffin for In-Stent Restenosis?∗ 16
Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials 16
The role of atherectomy in the treatment of lower extremity peripheral artery disease. 15
Multi-slice computed tomography assessment of stent position in a patient with acute coronary syndrome and anomalous origin of the coronary arteries : online article - case report 15
Geographical differences in the ratio of percutaneous and surgical myocardial revascularization procedures in the treatment of coronary artery disease 15
Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction 15
Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts 15
Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation: A Systematic Review 15
Totale 2.639
Categoria #
all - tutte 16.718
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.718


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020123 0 0 0 0 5 0 1 1 6 37 45 28
2020/202187 14 2 8 5 2 9 1 1 20 7 13 5
2021/2022494 4 1 8 1 1 21 2 20 89 6 62 279
2022/2023896 123 63 21 56 94 76 6 49 109 226 63 10
2023/2024686 22 128 116 36 26 25 15 89 19 26 117 67
2024/2025426 191 215 16 4 0 0 0 0 0 0 0 0
Totale 3.125